BioSpace News Archive

Drug Development

Actinium to Announce Interim Results from Pivotal Phase 3 SIERRA Trial on Conference Call Scheduled for Monday, October 28th

Management will be accompanied by Sergio Giralt, M.D., Chief Attending Physician, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center to present data from 50 percent enrollment in the Phase 3 trial

October 24, 2019
·
5 min read
Policy

Soligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition

Active Ingredient in SGX301 for the Treatment of Cutaneous T-Cell Lymphoma

October 24, 2019
·
9 min read
Drug Development

MaxCyte Advances Phase I Clinical Trial of Lead CARMA™ mRNA-based Cell Therapy to Third Cohort of Patients

CARMA platform offers faster manufacturing speeds, broader therapeutic applications, combination opportunities and repeat dosing potential

October 24, 2019
·
3 min read
Business

ADVANZ PHARMA Corp. Announces Release Date for Third Quarter 2019 Results

ADVANZ PHARMA Corp. announced it intends to release its third quarter, 2019 financial results before market open on Thursday, November 7, 2019..

October 24, 2019
·
5 min read
Drug Development

AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR‑RD‑02 for the Treatment of Gaucher Disease

AVROBIO, Inc., announced that the U.S. Food and Drug Administration has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-02, for the treatment of Gaucher disease.

October 24, 2019
·
6 min read
Policy

U.S. FDA Clears GI Scientific’s ScopeSeal®, the Only Single-Use Disposable Device Indicated to Significantly Reduce Duodenoscope Contamination During ERCP Procedures

Preserves the superior optical, navigation, air/water and instrument delivery capability of reusable duodenoscopes

October 24, 2019
·
5 min read
Drug Development

Asana BioSciences to Present Phase 1 Clinical Safety and Efficacy Data of Oral, Once-Weekly, ASN007, a Novel ERK 1/2 Inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present ASN007 data on clinical safety and efficacy in solid tumor patients at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference to be held in Boston, MA on October 26-30, 2019.

October 24, 2019
·
3 min read
Pharm Country

European Commission Approves Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection

Bristol-Myers Squibb Company announced that the European Commission has approved Opdivo flat dosing schedule of 240 mg infused over 30 minutes every two weeks or 480 mg infused over 60 minutes every four weeks for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

October 24, 2019
·
33 min read
Drug Development

Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 “Process A” for Fanconi Anemia

First Four “Process A” Patients Demonstrate Long-Term Evidence of Increasing and Durable Engraftment Resembling FA Mosaic Patients

October 24, 2019
·
9 min read
Business

Baxter Reports Preliminary Third Quarter 2019 Operating Results

The Company announces internal investigation of misstatements in previously reported non-operating income related to foreign exchange gains and losses

October 24, 2019
·
17 min read